Signals, Powered By EquityPandit
Cipla has received final approval for generic version of Dacogen, from the US health regulator, which is suggested for treatment of myelodysplastic syndromes.
Cipla in a BSE filing said, “it has received final approval for its abbreviated new drug application (ANDA) for Decitabine Injection 50 mg single-use sterile vial from the United States Food and Drug Administration (USFDA).”
Further, the product which has received approval is a generic equivalent of Otsuka America Pharmaceutical Inc’s Dacogen and it is available for shipping immediately.
